We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry.
- Authors
Erridge, Simon; Leung, Ophilia; Holvey, Carl; Coomber, Ross; Beri, Sushil; Khan, Shaheen; Weatherall, Mark W.; Rucker, James J.; Platt, Michael W.; Sodergren, Mikael H.
- Abstract
Introduction: While there is increasing evidence of the effects of cannabis‐based medicinal products (CBMPs) on health‐related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity of studied CBMPs. This study aims to analyze changes in HRQoL in patients prescribed a homogenous selection of CBMPs. Methods: Primary outcomes were changes in patient‐reported outcomes (PROMs) at 1, 3, 6, and 12 months from baseline. The secondary outcome was an adverse events analysis. Statistical significance was defined as p < 0.050. Results: 1378 patients prescribed Adven® CBMPs (Curaleaf International, Guernsey, UK) were included in the final analysis. 581 (42.16%) participants were current users of cannabis at baseline. 641 (46.51%), 235 (17.05%), and 502 (36.43%) patients were treated with oils, dried flowers, or a combination of the two, respectively. Improvements were found in all PROMs in each route of administration at 1, 3, 6, and 12 months from baseline (p < 0.010). Those prescribed dried flower only or both oils and dried flower experienced greater improvements in GAD‐7, SQS, and EQ‐5D‐5L index values at 12 months (p < 0.050). There was no difference in outcomes between those prescribed dried flower only or dried flower with oils (p > 0.050). 3663 (265.82%) adverse events were reported by 297 (21.55%) patients. Conclusion: There was an associated improvement in self‐reported anxiety, sleep quality, and HRQoL in patients treated with the CBMPs. Those prescribed treatment formulations including dried flower were most likely to show a clinical improvement. However, these results must be interpreted with caution given the limitations of study design.
- Subjects
GUERNSEY (Channel Islands); UNITED Kingdom; MEDICAL registries; MEDICAL marijuana; SLEEP quality; MEDICAL supplies; QUALITY of life; DROWSINESS
- Publication
Neuropsychopharmacology Reports, 2023, Vol 43, Issue 4, p616
- ISSN
2574-173X
- Publication type
Article
- DOI
10.1002/npr2.12403